Variation in human gut microbiota impacts tamoxifen pharmacokinetics

Area of Science:

• Pharmacology
• Microbiology
• Oncology

Background:

• Tamoxifen is a primary drug for breast cancer recurrence prevention, but patient responses vary significantly.
• Existing methods using genetics or liver enzymes fail to predict individual tamoxifen efficacy.
• Variable patient response to tamoxifen has substantial socioeconomic implications.

Purpose of the Study:

• To investigate the influence of gut bacteria on tamoxifen pharmacokinetics.
• To explore the role of gut microbiome enzymatic activity in tamoxifen metabolism.
• To identify factors contributing to differential patient responses to tamoxifen therapy.

Main Methods:

• Utilized gnotobiotic and antibiotic-treated mouse models to study tamoxifen pharmacokinetics.
• Employed 16S rRNA gene sequencing to analyze gut microbiota composition.
• Conducted metabolomics to assess microbiome metabolic profiles.
• Assessed the activity of beta-glucuronidase (GUS) enzymes on tamoxifen metabolites.

Main Results:

• Gut bacteria and prolonged exposure were found to heavily influence tamoxifen pharmacokinetics.
• Tamoxifen did not alter overall gut microbiota composition or abundance.
• Metabolomics revealed diverse enzymatic activities within gut microbiomes affecting tamoxifen metabolism.
• Variability in beta-glucuronidase (GUS) enzyme activity across human gut microbiomes impacts tamoxifen metabolite processing.

Conclusions:

• The gut microbiome plays a critical role in tamoxifen's pharmacokinetics.
• Enzymatic diversity within the gut microbiome contributes to variable patient responses to tamoxifen.
• Understanding the gut microbiome's role can lead to tailored tamoxifen therapies for improved breast cancer recurrence prevention.